Table 1.

Major published subgroup analyses of the StoRMI trial

Subgroup	Patient characteristics	PANSS score mean changes	SF-36 changes etc	Treatment-emergent adverse events	Reference
Switch from first-generation antipsychotic	100 patients switched from oral drug, 565 from depot medication	− 15.3 ± 17.5 for switch from oral drug; –9.1 ± 19.5 for switch from depot drug	CGI-S, GAF, SF-36 improved on all meaures	58.0% for switch from oral drug; 60.4% for switch from depot drug	Marinis et al 2007
Switch from monotherapy with Risperdal oral	568 patients (60% men, age 36–40 yr); 429 (75%) completed 6 mo	− 11.9 ± 17.3, − 7.7 ± 19.4), and − 8.7 ± 20.8, for the patients pre- treated with 4 mg or less, 4–6 mg, and >6 mg oral risperidone	Improvements were reported in all domains for the >6 mg pre-trial dosage group, significant in Role Physical and Role Emotional	53% in the ≤ 4 mg, 56% in the 4–6 mg, and 62% in the >6 mg pre-trial oral risperidone dosage group, resp; 55% overall	Schmauss et al 2007
Young adults	119 patients (age 18–30 yr)	Consistently improved	One third of the patients considered themselves to be either ‘not ill’ or ‘borderline ill’ at endpoint compared with 6 per cent at baseline	Not reported	Saleem et al 2004
Elderly persons	52 patients (age 65 + yr)	− 15.8 ± 19.9	Improvements reported in all domains	69%	Kissling et al 2007
Negative symptoms	842 patients with a PANSS negative subscale score of 21 or higher, which was higher than their positive subscale score	− 15.4 ± 20.4 for total PANSS, − 2.2 ± 5.9 for pos. subscale, − 6.1 ± 6.3 for neg. subscale	Improvements reported in all domains	58%	Curtis et al 2008
Schizoaffective disorder	119 patients (52% male, age 22–74 yr)	− 8.5	70% reported “good” or “very good” satisfaction	Not reported	Mohl et al 2004